Subsets of tumor-infiltrating NK cells express CTLA-4 and CD28, and CTLA-4 blockade was found to inhibit IFN-γ release by NK cells on coculture with mature DCs.81 In summary, like anti-PD1/PD-L1 therapies, anti-CTLA-4 therapy is capable of inducing global shifts in tumor-infiltrating innate immune subsets. The gene discussed is CTLA4; the disease is neoplasm.